Please ensure Javascript is enabled for purposes of website accessibility

3 Dividend Stocks Yielding More Than 5% That Are Safe Buys Right Now

By Keith Speights – Apr 28, 2020 at 6:01AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

High yields. Relatively low worries.

The higher a dividend yield is, the riskier the dividend is? This rule of thumb is applicable in many cases. Some stocks have really high dividend yields because there's an underlying problem that caused share prices to fall significantly. Those problems, at least in some cases, could eventually cause the dividends to be slashed.

But the rule of thumb isn't true for every dividend stock. Here are three dividend stocks with high yields (5% or more) that are safe buys right now.

Bag with dividends printed on it underneath an umbrella

Image source: Getty Images.

1. AbbVie

AbbVie (ABBV -1.29%) currently offers a dividend yield of more than 5.6%. The big drugmaker's dividend program boasts an impeccable history. AbbVie has increased its dividend for 47 consecutive years. And since being spun off from Abbott Labs in 2013, those dividend hikes have been quite substantial, with a total dividend increase of 195%.

But isn't AbbVie a high risk with its top-selling drug Humira facing biosimilar competition in Europe with more biosimilar rivals on the way in the U.S. within the next three years? I don't think so. The company has been making moves for years to lower its reliance on Humira.

One key part of that strategy was introducing new drugs. AbbVie's acquisition of Pharmacyclics in 2015 brought blockbuster cancer drug Imbruvica into its lineup. The company's internal research and development is also paying off nicely, with AbbVie launching two immunology drugs with blockbuster potential last year -- Rinvoq and Skyrizi. 

AbbVie expects to wrap up another acquisition soon that will diversify its revenue even more. The company recently struck a deal with the Federal Trade Commission that should clear the way for it to close its pending acquisition of Allergan in May. The deal will give AbbVie several products with rising sales, notably including Botox and antipsychotic drug Vraylar.

2. AT&T

Like AbbVie, AT&T (T -2.12%) is a member of the Dividend Aristocrats club, an elite group of S&P 500 stocks that have raised their dividends for at least 25 years. AT&T's streak of dividend hikes now stands 36 years in a row. And its dividend yield of 7% is sure to make investors' mouths water.

To be sure, AT&T faces some challenges. Its television business continues to struggle mightily. The company has lost TV subscribers for seven consecutive quarters. AT&T even lost streaming customers in the first quarter of 2020 when many people were stuck at home due to shelter-in-place orders and increased their overall streaming usage.

However, this issue doesn't make AT&T an unsafe stock to buy. For one thing, its TV unit remains profitable. The company also will launch its new HBO Max streaming service in May.

More importantly, though, AT&T's wireless business continues to perform well. Its wireless network has been named as the best network in the U.S. and the fastest network for five quarters in a row. With greater opportunities ahead as 5G networks are adopted, AT&T should be able to keep its wireless momentum going.

3. Brookfield Infrastructure Partners/Brookfield Infrastructure Corporation

I've included both Brookfield Infrastructure Partners (BIP -3.56%) and Brookfield Infrastructure Corporation (BIPC -3.91%) on the list of safe high-yield dividend stock to buy. Brookfield Infrastructure Partners recently conducted a unique kind of stock split to give investors an alternative to buy shares of a corporation instead of a limited partnership, which comes with some tax implications. Brookfield Infrastructure Corporation is a subsidiary of Bookfield Infrastructure Partners, with the two companies economically equivalent.

Regardless of which of these two stocks you buy, you'll get a great dividend yield of nearly 5.8%. You'll also own part of a strong infrastructure business that should deliver solid total returns for a long time to come.

Brookfield Infrastructure owns and operates infrastructure assets that are highly diversified across sectors and geographical regions. These assets include cell towers, data centers, electricity distribution systems, natural gas pipelines, railroads, toll roads, and more. They're the kinds of infrastructure assets that rake in money regularly in good economic times and when times aren't so great.

The long-term growth prospects for Brookfield Infrastructure looks attractive. The company continually evaluates its assets and sells off lower-performing ones to reinvest into new assets with the potential to generate higher returns. Brookfield Infrastructure even refers to itself as a "grow-tility" -- combining the relatively safety of a utility company with stronger growth prospects that most utilities offer.

I think both of the stocks under the Brookfield Infrastructure umbrella are great picks for investors seeking high yields that they don't have to worry about.

Keith Speights owns shares of AbbVie, Brookfield Infrastructure, and Brookfield Infrastructure Partners. The Motley Fool recommends Brookfield Infrastructure and Brookfield Infrastructure Partners. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Brookfield Infrastructure Partners L.P. Stock Quote
Brookfield Infrastructure Partners L.P.
$38.20 (-3.56%) $-1.41
AbbVie Inc. Stock Quote
AbbVie Inc.
$141.21 (-1.29%) $-1.85
Brookfield Infrastructure Corporation Stock Quote
Brookfield Infrastructure Corporation
$45.24 (-3.91%) $-1.84
AT&T Inc. Stock Quote
AT&T Inc.
$15.67 (-2.12%) $0.34
Allergan plc Stock Quote
Allergan plc
Abbott Laboratories Stock Quote
Abbott Laboratories
$99.84 (-0.83%) $0.84

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.